Riverstone was my first value-growth stock and has been a large part of my portfolio since then. I clearly remember making my first purchase at $0.81 on 31st March 2014, using my phone app, while accompanying a group of children for an excursion at Gardens By the Bay as part of a Community Involvement Program (CIP). Back then, it was near the all-time high of $0.84, I was hesitant to take the leap of faith at first due to the fear of it retracing, but thank goodness I did it anyways. Fast forwards to today, Riverstone has appreciated 182.7% excluding dividends in the span of roughly 1.7 years. What seemed like an all time high then looks minuscule now doesn’t it? Below are the following reasons why I am still vested in this company and think that there’sstill room for growth
Riverstone is in the business of manufacturing cleanroom gloves for the electronic industry and medical gloves for the healthcare industry. This is a relatively simple and understandable business. Riverstone obtains raw material to manufacture the gloves and sells them to its customers. Riverstone is currently well-positioned to benefit from the change in trend of preference for nitrile gloves (which Riverstone manufactures) compared to latex gloves (which causes allergic reactions). The business economics of gloves is excellent as it is consumable, recurring in nature, and takes up a small percentage of COGS. For example, after a doctor examines a patient, he has to throw way that pair of gloves and don on a new pair before examining the next patient. This process repeats itself until the gloves run out and the doctor has to obtain more gloves, which takes up only a small fraction of operating costs of running a clinic/hospital, so it is unlikely that the doctor will think twice about the cost of gloves. This makes customers of Riverstone sticky and loyal. In the cleanroom industry, Riverstone has a 60% market share. Though the same cannot be said for the healthcare industry, Riverstone has been getting overwhelming demands from potential customers that are seeking to diversify their supplier base. Furthermore, with the rapid urbanisation of the emerging markets and China, demand for medical gloves is bound to grow.
In April 2013, as part a response to the overwhelming increase in demand for gloves, Riverstone acquired a 30-acre plot of land in Taiping, Perak, Malaysia. The plan was to build a new production facility, constructed over 6 phases, adding 1 billion gloves in production capacity per phase. Each phase was to take approximately 1 year to complete. Hence, given the clear expansion plans all the way to 2019, Riverstone still has much room to boost its top line while enjoying economies of scale which will further improve its bottom line and margins. In addition, the long-term strengthening of the USD and weakening of the MYR will further boost earnings as a large part of Riverstone’s revenues are in USD while a large part of its expenses are in MYR.
|Year||Phase||Year-End Production Capacity (in billions)||Capacity Growth (%)|
Riverstone is currently led by its Founder, Executive Chairman, and Chief Executive Officer Wong Teek Son. He owns 47.51% of Riverstone. Chief Operating Officer and Executive Director Lee Wai Keong owns 11.66%. Group Business Development Manager and Executive Director Wong Teck Chong, brother of Wong Teek Son, owns 3.98%. In aggregate the key management owns a total of 63.09% of Riverstone. Allow me to side track for a moment. Although not statistically proven, based on my experience, companies who are led by their founders with significant stakes tend to do much better than professionally managed companies. Think Apple, Amazon, Walmart, Microsoft, Facebook, Starbucks, and Alibaba. Founders are passionate, self motivated, and driven. They treat their company like their children and would not sacrifice long-term gains for short-term prosperity. The same cannot be said for professionally managed companies where executives are paid monthly or yearly wages. The best example, is the recent emissions scandal, of Volkswagen. The CEO knew what was going but kept quiet about it. When found out, he quickly resigned and is likely to obtain a $32 million pension after leaving! In the end, its the shareholders who would foot that bill plus the billions in fines Volkswagen would have to pay as a result of this scandal.
Riverstone’s management has also proved to be efficient allocators of capital. They funded the entire Phase 1 and 2 internally without incurring debt and issuing shares. With excess cash they have also redistributed it back to shareholders in the form of increasing dividends (see chart below). Not to mention that Riverstone is completely debt free. A company without debt cannot go bankrupt. Riverstone’s management’s execution of its growth plans thus far has been excellent, which plans not only going according to plan but accelerating due to the high demand and enquires from existing and potential customers.
Riverstone’s financials are solid, which validates the strength and sustainability of its business and the management’s competence in allocating capital, managing costs, while pursuing growth. Since 2005, Riverstone’s revenues and profits has been steadily increasing. Due to the non-cyclical and resilient nature of the glove business, Riverstone actually made more during the financial crisis of 2008-2009. Riverstone also has superior margins vs. its competitors due to its niche in cleanroom gloves which command better margins. This has enabled it to produce high quality ROEs in excess of 16% from 2005-2015 with little to no debt. Riverstone is also a cash generative business with steadily increasing cashflow from operations. This enables Riverstone to fund its growth internally and pay increasing dividends. Free cashflow has been positive over the years but turned negative last year due to the CAPEX used to fund the company’s growth, which is acceptable.
I first got Riverstone at a valuation of roughly 13x P/E. Now, it is valued at 21x P/E. Which means that the share price has out paced the growth in the company’s earnings. Some people may be concerned that Riverstone’s best days are over and is due for a correction, but I believe otherwise. In my opinion, Riverstone still has much room to grow and such above average rates of growth should garner higher, if not, current valuations. Riverstone is currently valued below the peer average despite having superior growth rates and ROEs compared to its peers. Furthermore, the glove industry should be able to sustain such valuations in the 20s due to its non-cyclical, resilient, and medical industry-related nature.In fact, it is not uncommon for medical companies to have lofty valuations. Raffles Medical Group is currently valued at 36x P/E. Singapore O&G = 38x P/E. Q&M Dental = 43.21x P/E. I believe Riverstone should be valued at 25x P/E (peer average) at the very least given the reasons mentioned above. Assuming the growth plans materialises all the way to 2019, increases in production capacity is met with proportionate demand, ASP remains constant, Riverstone could potentially be worth $4.30 by 2018-2019.
Positive catalyst include the recently proposed 1-1 bonus issue. If passed, Riverstone’s trading liquidity will improve and that would allow greater participation by investors (retail or institutional). This could give Riverstone’s valuation, and thus, its share price a further boost.
- Simple and Understandable Business
- Clear Growth Plans – Up till 2019
- Beneficiary of Strengthening USD and Weakening MYR
- Founder-led business with significant stake in business
- Excellent growth execution
- Increasing dividends
- Superior margins, returns on equity, and debt free
- Funds its growth internally
- Potential increase in valuation due to proposed 1-1 bonus issue
- Potentially worth $4.30 by 2018-2019 (Industry Average 25x P/E , EPS growth tagged with Volume growth till 2019)
- Growth plans do not materialise due to unforeseen circumstances
- Weakening USD and Strengthening MYR
- Sudden spike in raw material prices
- Oversupply of gloves causing ASPs to plunge
- Something bad happens to the Founder
- Bad execution of expansion plans